Three months ago, Robert M Califf, commissioner of the US Food and Drug Administration (USFDA) visited India to strengthen efforts on development, supply, and quality of drugs. For the US, where more than nine out of 10 prescriptions dispensed are generic drugs, India is a critical partner, responsible for supplying a substantial portion of these drugs. During his visit, the commissioner said in an interview with television channel CNBC-TV18
usfda: Closer USFDA lens will keep Indian pharma edgy, but companies now better placed to handle the glare
